A single dose, globally accessible vaccine to combat emerging SARS-CoV-2 variants
Project Member(s): Hansbro, P.
Funding or Partner Organisation: Medical Research Future Fund (MRFF Coronovirus Scheme)
Medical Research Future Fund (MRFF Coronovirus Scheme)
Start year: 2021
Summary: The emergence of highly transmissible SARS-CoV-2 variants threatens to derail COVID-19 control efforts. We have developed a next-generation vaccine, delivered as a single dose, that targets these variants. In this proposal we willl undertake late-stage pre-clinical testing to determine the optimal vaccine formulation, define protective efficacy against SARS-CoV-2 infection and assess vaccine safety/tolerability. Outcomes will be used to fast track vaccine progression to clinical testing.
FOR Codes: Respiratory diseases , Virology , Infectious Diseases, Respiratory System and Diseases (incl. Asthma), Clinical health